Nesina Related Published Studies
Well-designed clinical trials related to Nesina (Alogliptin)
Efficacy and safety of alogliptin added to insulin in Japanese patients with type
2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial
followed by an open-label, long-term extension phase. [2014]
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2
diabetes mellitus. [2013]
Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with
type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an
open-label, long-term extension study. [2012]
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with
type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an
open-label long-term extension study. [2011]
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. [2009]
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl
peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled,
multiple-dose study in adult patients with type 2 diabetes. [2008]
Other research related to Nesina (Alogliptin)
Rationale, design, and baseline characteristics of a trial for the prevention of
diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects
of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). [2013]
Alogliptin benzoate for the treatment of type 2 diabetes. [2012]
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4)
inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin,
and vildagliptin efficacy results. [2012]
Pharmacokinetics of alogliptin when administered with food, metformin, or
cimetidine: a two-phase, crossover study in healthy subjects. [2010]
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces
HbA(1C) without causing weight gain or increased hypoglycaemia. [2009]
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to
metformin therapy in patients with type 2 diabetes inadequately controlled with
metformin monotherapy: a multicentre, randomised, double-blind,
placebo-controlled study. [2009]
Other possibly related research studies
Cardiovascular effects of incretin therapy in diabetes care. [2014]
Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4
inhibitors : meta-regression analysis of 78 randomized controlled trials with
20,053 patients. [2014]
Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type
2 diabetic patients: a systematic review. [2013]
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes:
meta-analysis of randomized controlled trials. [2011]
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk
of drugs for type 2 diabetes on clinical development. [2011]
Efficacy and safety of incretin based therapies: clinical trial data. [2009]
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical
practice. [2009]
|